Stockscreener 앱 받기
1.98
5.26%
-0.11
시간 외 거래:
1.98
전일 마감가:
$2.09
열려 있는:
$2.06
하루 거래량:
314.71K
Relative Volume:
0.24
시가총액:
$142.62M
수익:
-
순이익/손실:
$-117.50M
주가수익비율:
-0.825
EPS:
-2.4
순현금흐름:
$-114.31M
1주 성능:
-1.49%
1개월 성능:
+21.47%
6개월 성능:
-39.08%
1년 성능:
-73.24%
1일 변동 폭
$1.945
$2.10
1주일 범위
$1.9001
$2.14
52주 변동 폭
$1.31
$8.23
엔카르타 Stock (NKTX) Company Profile
명칭
Nkarta Inc
전화
(925) 407-1049
주소
1150 VETERANS BOULEVARD, SOUTH SAN FRANCISCO
NKTX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
NKTX
Nkarta Inc
|
1.98 | 142.62M | 0 | -117.50M | -114.31M | -2.40 |
|
VRTX
Vertex Pharmaceuticals Inc
|
500.19 | 127.64B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
603.58 | 65.95B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
656.65 | 37.92B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
273.55 | 32.98B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ONC
Beigene Ltd Adr
|
254.16 | 26.92B | 3.81B | -644.79M | -669.77M | -6.24 |
엔카르타 Stock (NKTX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-10-09 | 개시 | Rodman & Renshaw | Buy |
| 2024-08-14 | 업그레이드 | Raymond James | Outperform → Strong Buy |
| 2024-03-22 | 다운그레이드 | Raymond James | Strong Buy → Outperform |
| 2022-12-22 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2022-10-10 | 개시 | Canaccord Genuity | Buy |
| 2022-07-28 | 개시 | Needham | Buy |
| 2022-07-18 | 개시 | SVB Leerink | Outperform |
| 2022-03-11 | 개시 | Raymond James | Outperform |
| 2022-03-08 | 개시 | H.C. Wainwright | Buy |
| 2022-01-06 | 개시 | William Blair | Outperform |
| 2021-11-18 | 개시 | SMBC Nikko | Outperform |
| 2021-07-16 | 개시 | Oppenheimer | Outperform |
| 2020-08-04 | 개시 | Cowen | Outperform |
| 2020-08-04 | 개시 | Evercore ISI | Outperform |
| 2020-08-04 | 개시 | Mizuho | Buy |
| 2020-08-04 | 개시 | Stifel | Buy |
모두보기
엔카르타 주식(NKTX)의 최신 뉴스
Uncovering the Potential of Nkarta Inc (NKTX) Stock - investchronicle.com
A stock that deserves closer examination: Nkarta Inc (NKTX) - uspostnews.com
Nkarta Inc (NKTX) may enjoy gains as insiders got busy in the recent days - knoxdaily.com
Daily Market Movement: Nkarta Inc (NKTX) Sees a -4.74 Decrease, Closing at 2.01 - DWinneX
Geode Capital Management LLC Has $2.94 Million Stock Position in Nkarta, Inc. (NASDAQ:NKTX) - Defense World
Layoff Tracker: Ono Cuts 83 Employees in Massachusetts - BioSpace
Nkarta Inc’s Market Journey: Closing Weak at 1.56, Down -4.29 - DWinneX
A stock that deserves closer examination: Estrella Immunopharma Inc (ESLA) - uspostnews.com
Technical analysis of Nkarta Inc (NKTX) stock chart patterns - uspostnews.com
Market Momentum Report: Nkarta Inc (NKTX)’s Negative Close at 2.18 - DWinneX
Insider Sale Alert: Nkarta Inc [NKTX] – Is it Time to sell? - knoxdaily.com
A Tale of Resilience: Nkarta Inc Amid Stock Market Turbulence - investchronicle.com
Nkarta, Inc. (NASDAQ:NKTX) Receives Average Rating of “Buy” from Brokerages - Defense World
JPMorgan Chase & Co. Raises Stock Position in Nkarta, Inc. (NASDAQ:NKTX) - Defense World
Nkarta (NKTX) Upgraded to Buy: Here's Why - NewsBreak: Local News & Alerts
Wellington Management Group LLP Boosts Stock Holdings in Nkarta, Inc. (NASDAQ:NKTX) - Defense World
Natural Killer Cell Therapy Market Hits New High | Major Giants Nkarta Therapeutics, Kiadis Pharma - newstrail.com
American Century Companies Inc. Buys 7,378 Shares of Nkarta, Inc. (NASDAQ:NKTX) - Defense World
Sei Investments Co. Invests $57,000 in Nkarta, Inc. (NASDAQ:NKTX) - Defense World
Nkarta’s (NKTX) Buy Rating Reiterated at Needham & Company LLC - Defense World
Nkarta (NASDAQ:NKTX) Earns "Buy" Rating from Needham & Company LLC - MarketBeat
Prudential Financial Inc. Sells 49,500 Shares of Nkarta, Inc. (NASDAQ:NKTX) - Defense World
CAR NK Expert With 25-Year Track Record Strengthens Senti Bio's Scientific Leadership - Stock Titan
Thrivent Financial for Lutherans Makes New Investment in Nkarta, Inc. (NASDAQ:NKTX) - Defense World
Charles Schwab Investment Management Inc. Cuts Stock Holdings in Nkarta, Inc. (NASDAQ:NKTX) - Defense World
Nkarta to Participate in an April Investor Conference - GlobeNewswire
NK Cell Pioneer Nkarta Takes Center Stage at Major Healthcare Conference - Stock Titan
Leerink Partnrs Has Bullish Outlook for Nkarta Q1 Earnings - The AM Reporter
Nkarta: Grinding Lower, Trying To Find Support (NASDAQ:NKTX) - Seeking Alpha
Nkarta: Betting On The Turnaround (NASDAQ:NKTX) - Seeking Alpha
William Blair Estimates Nkarta’s Q1 Earnings (NASDAQ:NKTX) - Defense World
What is HC Wainwright’s Forecast for Nkarta Q1 Earnings? - Defense World
Nkarta, Inc. (NASDAQ:NKTX) Receives $14.86 Average Price Target from Brokerages - Defense World
Stifel Nicolaus Has Lowered Expectations for Nkarta (NASDAQ:NKTX) Stock Price - Defense World
What is HC Wainwright’s Forecast for Nkarta Q4 Earnings? - Defense World
Needham & Company LLC Reaffirms “Buy” Rating for Nkarta (NASDAQ:NKTX) - Defense World
Nkarta’s Strategic Workforce Reduction and Clinical Progress Justify Buy Rating - TipRanks
Analysts Adjust Price Targets For Nkarta And Bicara - Evrim Ağacı
Why Is Autoimmune Disease Focused Nkarta Stock Trading Higher On Thursday? - Benzinga
Analysts Offer Insights on Healthcare Companies: Allurion Technologies (ALUR), Perspective Therapeutics (CATX) and Nkarta (NKTX) - The Globe and Mail
Nkarta to lay off staff, senior leadership, in bid to advance autoimmune cell therapy - BioPharma Dive
Stifel cuts Nkarta stock price target to $14, maintains buy rating - Investing.com India
Nkarta to lay off 34% of staff; Savara’s debt financing deal - Endpoints News
H.C. Wainwright maintains Buy on Nkarta stock with $18 target By Investing.com - Investing.com South Africa
H.C. Wainwright maintains Buy on Nkarta stock with $18 target - Investing.com
Nkarta lays off 3rd of staff to fund autoimmune CAR NK program - Fierce Biotech
엔카르타 (NKTX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.39%
3.66%
자본화:
|
볼륨(24시간):